Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KVAC

Keen Vision Acquisition Corp

May 01 • 04:00PM ET

12.22

+0.07 0.58 %

Financial • Shell Companies • USA • Micro • NASD

Scroll to Statements

Index	-	P/E	65.21	EPS (ttm)	0.19	Insider Own	80.20%	Shs Outstand	9.24M	Perf Week	0.16%
Market Cap	67.48M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.09M	Perf Month	1.83%
Enterprise Value	70.14M	PEG	-	EPS next Q	-	Inst Own	89.66%	Short Float	0.01%	Perf Quarter	2.95%
Income	1.91M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.09	Perf Half Y	6.17%
Sales	0.00M	P/B	2.26	EPS next Y	-	ROA	3.00%	Short Interest	0.00M	Perf YTD	4.00%
Book/sh	5.41	P/C	6748.00	EPS next 5Y	-	ROE	3.29%	52W High	12.43 -1.69%	Perf Year	7.95%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	- -	ROIC	3.82%	52W Low	11.25 8.62%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.00% 0.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-54.68%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.15	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.01	EPS Q/Q	-38.93%	SMA20	1.39%	Beta	-0.03	Target Price	-
Payout	0.00%	Debt/Eq	0.05	Sales Q/Q	-	SMA50	2.38%	Rel Volume	0.03	Prev Close	12.15
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	7.21%	Avg Volume	1.17K	Price	12.22
IPO	Sep 15, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	30	Change	0.58%

Jul-15-25 08:00AM	Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy (GlobeNewswire)
Jun-24-25 08:00AM	Mederas Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome (GlobeNewswire)
Jun-13-25 08:00AM	Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025 (GlobeNewswire)
May-19-25 08:00AM	Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress (GlobeNewswire)
May-12-25 08:00AM	Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress (GlobeNewswire)
08:00AM	Loading…
Apr-01-25 08:00AM	Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit (GlobeNewswire)
Mar-20-25 08:00AM	Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction (GlobeNewswire)
Mar-11-25 12:53PM	Medera Completes Patient Dosing for Heart Failure Treatment (Exec Edge)
09:09AM	Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction (GlobeNewswire)
Feb-10-25 08:00AM	Mederas Novoheart Expands Human Cardiac Research with CTScreen Installation at University Medical Center, Utrecht (GlobeNewswire)
Feb-07-25 08:00AM	Medera, Inc. to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Dec-18-24 08:00AM	Medera's Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening (GlobeNewswire)
Dec-10-24 08:00AM	Medera's Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing (GlobeNewswire)
Oct-31-24 08:00AM	Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology (PR Newswire)
Oct-24-24 08:00AM	Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction (PR Newswire)
11:57AM	Loading…
Sep-05-24 11:57AM	Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp. (Exec Edge)
08:00AM	Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation (PR Newswire)

Keen Vision Acquisition Corp. is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, and reorganization or similar business combination. The company was founded on June 18, 2021 and is headquartered in Summit, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KVAC

Keen Vision Acquisition Corp

Upgrade your Finviz experience